At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Association Between Risk Scores for Genetic Variants and Percentage of Time in Therapeutic Range for Participants With Atrial Fibrillation, Deep Vein Thrombosis, and/or Intracardiac Thrombosis Taking Warfarin
In Brief
An observational study for Atrial Fibrillation and 4 related conditions. Completed, enrolled 200 participants across 1 site.
Detailed Summary
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, bleeding event, ischemic stroke, death) in participants taking warfarin for atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and/or intracardiac thrombosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism, Venous Thromboembolic Disease
CountriesUnited States
CollaboratorsSanta Clara Valley Medical Center
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedMar 2019
Primary CompletionSep 2022
TodayJul 2026
First PostedMar 29, 2019
Enrollment StartFeb 11, 2019
Primary CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.3 years ago